Navigation Links
Two New Drugs For Breast Cancer Show Promise

Two of the most promising breast cancer drugs are raloxifene and lapatinib, according to researchers who revealed their findings// at he European Breast Cancer Conference (EBCC-5). Raloxifene is a drug that was first developed to treat osteoporosis in women.

It belongs to a class of drugs called selective benzothiophene oestrogen receptor modulator (SERM) and exerts an anti-estrogen effect. Hence it's use in breast cancer. In the trials where raloxifene was used as an osteoporosis drug, it also appeared to prevent the formation of new hormone dependant breast cancers. The MORE (The Multiple Outcomes of Raloxifene Evaluation) study, which evaluated 7,705 women by either administering raloxifene or placebo to a group. The results of this trial are awaited. Another trial that aims to test the efficacy of raloxifene was conducted on 20,000 postmenopausal women in the US. The results of this trial are also awaited. However, women taking raloxifene are known to have an increased risk of developing deep vein thrombosis or pulmonary embolism as side effects. Another drug that is exciting researchers is lapatinib, which is given orally. The molecule is a subset of Epidermal Growth Factor Receptors (EGFR). Preliminary results suggest that the drug could kill cancer cells that are not killed by other breast cancer drugs. Dr F. Cardoso from the Jules Bordet Institute, Brussels, who is involved in the drug research said, "Raloxifene and lapatinib are exciting new drugs which will be of interest in prevention and treatment of breast cancer patients in the future." Contact: EBCC-5 Press Office stephanie.makin@toniclc.com 33-493-928-402 Federation of European Cancer Societies Source: Eurekalert
'"/>




Page: 1

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: